A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.

@article{Klotz2013AP3,
  title={A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.},
  author={Laurence H. Klotz and Irene Y McNeill and Marlene Kebabdjian and Liying Zhang and Joseph L. Chin},
  journal={European urology},
  year={2013},
  volume={63 5},
  pages={927-35}
}
BACKGROUND Androgen-deprivation therapy (ADT) induces loss of bone mineral density (BMD) and increases the risk of fractures in patients with prostate cancer (PCa). We sought to determine whether a weekly dose of alendronate, an oral bisphosphonate, could reduce this unwanted side-effect. OBJECTIVE To assess whether once-weekly oral alendronate therapy would maintain or improve BMD in men initiating ADT for localised PCa. DESIGN, SETTING, AND PARTICIPANTS A multicentre, double-blind… CONTINUE READING
26 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer

  • MR Smith, B Egerdie, N Hernández Toriz
  • N Engl J Med
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…